About this policy
CMS evidence review | evidence_type=MEDCAC Meeting | record_type=medcac_meeting | document_id=4 | meeting_date=2001-06-20
Coverage indications
Carnitine is an endogenous molecule that serves as a carrier in the transport of long-chain fatty acids across the inner mitochrondrial membrane, facilitating oxidation and energy production. Dialytic losses, combined with reduced renal synthesis and reduced intake of meat and dairy products, can cause carnitine deficiency in end stage renal disease (ESRD) patients. Levocarnitine injection has been approved by the Food and Drug Administration (FDA) for the "prevention and treatment of carnitine deficiency in ESRD patients who are undergoing dialysis. Levocarnitine injection was first approved by the in FDA 1992. The FDA approved the drug's indication for ESRD patients on December 15, 1999. Given inconsistencies among the fiscal intermediaries' local coverage policies for this drug, the Centers for Medicare and Medicaid Services (CMS) believes a national review is appropriate. Among other issues, CMS plans to examine, in this review, the clinical significance of carnitine deficiency and the issue of intravenous administration of carnitine supplementation versus oral administration.
Documentation requirements
Issue: Carnitine is an endogenous molecule that serves as a carrier in the transport of long-chain fatty acids across the inner mitochrondrial membrane, facilitating oxidation and energy production. Dialytic losses, combined with reduced renal synthesis and reduced intake of meat and dairy products, can cause carnitine deficiency in end stage renal disease (ESRD) patients. Levocarnitine injection has been approved by the Food and Drug Administration (FDA) for the "prevention and treatment of carnitine deficiency in ESRD patients who are undergoing dialysis. Levocarnitine injection was first approved by the in FDA 1992. The FDA approved the drug's indication for ESRD patients on December 15, 1999. Given inconsistencies among the fiscal intermediaries' local coverage policies for this drug, the Centers for Medicare and Medicaid Services (CMS) believes a national review is appropriate. Among other issues, CMS plans to examine, in this review, the clinical significance of carnitine deficiency and the issue of intravenous administration of carnitine supplementation versus oral administration. Minutes: Minutes of June 20, 2001 Meeting OPEN SESSION Baltimore Convention Center Baltimore, Maryland Attendees Thomas V. Holohan, MA, MD, FACP Chairperson Kimberly Long Executive Secretary Voting Members Kathy J. Helzlsouer, MD, MHS Robert C. Johnson, MS Ronald P. Jordan, RPh Mitchell Sugarman, MBA, MS Temporary Voting Member Emil P. Paganini, MD, FACP, FRCP Temporary Non-Voting Member Paul Metzger, MD Industry Representative Cathleen M. Dooley, MA Consumer Representative Christine M. Grant, JD CMS Representative Sean R. Tunis, MD, MSc Tuesday, June 20, 2001, 8:35 a.m. The Drugs, Biologics, and Therapeutics Panel met on June 20, 2001, to discuss the use of levo-carnitine (carnitine) in end stage renal disease (ESRD) patients. The meeting began with a reading of the conflict of interest statement, and the call to order. Clinical Background. Dr. Glenn Chertow from the University of California, San Francisco (UCSF), presented the Panel with an overview of the clinical background of carnitine deficiency, how it is acquired, and when administration of carnitine affects asthenia, malaise, muscle weakness, intradialytic cramps and hypotension, cardiomyopathy, EPO resistant anemia, and quality of life. He also explained the history of K/DOQI. The DOQI work group concluded that although the totality of evidence was unimpressive, a therapeutic trial could be reasonable. FDA Presentation. The FDA representative was unable to attend the meeting, but Dr. Tunis read a letter from the Director, Division of Metabolic and Endocrine Drug Products, summarizing the basis for FDA's approval of intravenous carnitine for the prevention and treatment of carnitine deficiency associated with ESRD in patients undergoing chronic hemodialysis. CMS Presentation. John Whyte, MD, MPH, discussed the reasons why the questions were referred to the Medicare Coverage Advisory Committee (MCAC), primarily because different groups expressed widely variant opinions about the same data. Because of this, a literature review followed by an open meeting was believed to be the best way to address the issue. Dr. Preston Klassen, MD, MHS, summarized the literature review conducted by the MCAC, Dr. Whyte then stated the questions the Panel would be asked to consider. Scheduled Public Comments. The Panel heard from 12 scheduled speakers, including repesentatives of Sigma Tau, the manufacturer of Carnitor injection; medical directors of CMS fiscal intermediaries from Georgia and Pennsylvania; a nephrologist from Ochsner Clinic in New Orleans; president of the National Association for Rare Disorders; two dialysis patients with history of carnitine treatment; a clinical nephrologist from University of California at Los Angeles (UCLA); the executive director of American Association of Kidney Patients (AAKP); a former senior endocrinologist at the FDA; and the executive director of Renal Beginnings, who gave a presentation on behalf of the Georgia Society of Nephrology (GSN). These individuals relayed their personal experience, as well as the policies of organizations they represented, concerning the topic under discussion. Review of Evidence by Panel Members. Dr. Holohan and Ms. Dooley presented a summary of the data provided by CMS. Dr. Holohan shared a series of tables summarizing results of studies for different indications. Ms. Dooley related the results of the various data to the specific questions posed by CMS. Open Public Comments. Five additional commenters of the general public gave presentations to the Panel. Open Panel Deliberations. The Panel held a lengthy discussion. At the outset, Dr. Tunis reminded the Panel that although the issue of cost had been brought up, it is not an issue for the Panel, which will make its recommendations based on the adequacy of the evidence. During the deliberations, several panelists expressed concern over the definition of carnitine deficiency since several of the presenters indicated that there should be criteria other than a simple percentage of serum carnitine before administering levo-carnitine. Panelists also noted that many of the issues presented were difficult to answer given the specific questions proposed by CMS. Several panelists commended Georgia on the guidelines they had developed and encouraged CMS to look at them when drafting any national coverage decision. Panelists specifically noted there was very little evidence presented showing the efficacy of one method of treatment compared to another. Final Panel Recommendations. After further discussion, the panel voted on the following three motions: (1) CMS to establish a mechanism to define carnitine deficiency in the ESRD patient population because there is adequate evidence that such a condition exists. The Panel voted unanimously in favor of that motion. (2) There is adequate evidence that indicates some patients benefit from levo-carnitine; upon establishment of rational guidelines that identify this patient population, Medicare coverage should be provided. The Panel voted unanimously in favor of that motion. (3) There is insufficient evidence to conclude that the route of administration, be it intravenous, oral, or dialysis fluid, is an important factor in the clinical safety of L-carnitine therapy in patients with ESRD on hemodialysis. The motion carries three to one, that the evidence is insufficient. Adjournment. The meeting adjourned at 4:20 p.m. I certify that I attended the meeting of the Drugs, Biologics, and Therapeutics Panel on June 20, 2001, and that these minutes accurately reflect what transpired. _________________________________ Kimberly Long Executive Secretary, CMS I approve the minutes of this meeting as recorded in this summary. ______________________________ Thomas V. Holohan, MA, MD, FACP Chairperson
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Code | Code system | Status in this policy |
|---|---|---|
| J1955 | HCPCS | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |